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Objective: While life expectancy is improving for persons
with spinal muscular atrophy, new physical complaints may
arise. To investigate this, we studied persons with a long
duration and severe course (high functional limitations) of
the disease.
Design: Cross-sectional descriptive study.
Subjects/Patients: Persons with spinal muscular atrophy.
Methods: Questionnaires and structured interviews on
prevalence of physical complaints and their duration. Of 190
questionnaires 99 were returned; of 23 persons (with the
longest disease duration and high functional limitation level)
selected for structured medical interviews 9 participated.
Results: Patterns common within and different between the
different types of spinal muscular atrophy were identiﬁed.
Of the 10 most common complaints, types 1–2 had a
signiﬁcantly higher prevalence of kyphoscoliosis, difﬁculty in
coughing, joint contractures and voice/speech problems,
while type 3 had a signiﬁcantly higher prevalence of fatigue.
No statistically signiﬁcant correlation was found between the
appearance of physical complaints and disease duration.
However, sleeping and swallowing problems were in the 5
most common complaints with the shortest mean time of
appearance. The structured interview revealed hyper-
mobility in the hand, suffusion of the eyes, and itching as new
complaints with high prevalence.
Conclusion: There are indications that the frequency of less
well-known physical complaints increases with ageing.
Key words: spinal muscular atrophy, ageing, physical
problems, physical complaints.
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INTRODUCTION
Life expectancy in general is currently increasing. This also
applies to persons with a progressive disease such as spinal
muscular atrophy (SMA), although there is a difference between
SMA type 2 (symptomatic at childhood, not able to walk) and
type 3 (symptomatic at childhood or adulthood, able to walk)
(typing according to Emery (1)). In large studies Zerres et al.
(2, 3) describe the life expectancy of people with SMA type 2
and type 3 as being better than predicted. People with SMA type
3, in particular, seem to have a normal life expectancy, although
progression of the disease varies between individuals. The rate
of progression is related to the severity of impairments such as
scoliosis or lung function (4, 5) and functional abilities (2, 6).
Several impairments in physical functions are described in
patients with SMA: contractures and scoliosis (5, 7), nutritional
problems (8, 9), restricted lung function (5, 10) and restricted
cardiac function (5, 11, 12). Although these impairments are
described, it is not always mentioned at which stage of the
disease they appear. Nowadays several impairments can be
treated effectively, for example spinal surgery can not only
correct the scoliosis, but also improve lung function (4), and
lung rehabilitation can increase life expectancy (10, 13). Thus,
with technical and medical improvements, life expectancy for
people with the more progressive types of SMA improves. The
question arises as to whether new physical complaints arise
related to SMA that previously were masked by life-threatening
symptoms or death.
To explore the possibility of new or less well-known
complaints, a descriptive cohort study was performed of the
physical impairments of persons with SMA types 2 and 3 with a
long duration of the disease (diagnosed at least 10 years before
and diagnosed before the age of 33 years). Particular attention
was focussed on the group with the most severe disease
progression (most functional limitations).
Two research questions were investigated: (i) Is there a
correlation between the appearance of (new) physical
complaints and the duration and severity of SMA? (ii) Is there a
difference in patterns of physical complaints between SMA
types 2 and 3?
MATERIAL AND METHODS
Study design
A descriptive cohort study was performed. Members of the Dutch
patients’ association for neuromuscular disorders (Vereniging Spier-
ziekten Nederland) known to have the diagnosis SMA (not necessarily
conﬁrmed with DNA analysis) were invited to participate. Inclusion
criteria were: the diagnosis was made at least 10 years ago and the
diagnosis had been established before the age of 33 years. A subgroup
was selected with the longest duration of the disease (as deﬁned by the
reported time between the ﬁrst symptoms and the date of the ques-
tionnaire) and the highest functional limitations (established by the
sickness impact proﬁle score, see below). Cut-off points (explained in
analysis) were determined for SMA type 1–2 as a disease duration of at
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least 31 years and a SIP-score higher than 24; for SMA type 3þ (for
grouping: see analysis) the cut-off points were a disease duration of at
least 41 years and a SIP-score higher than 19. The subgroups were asked
to participate in a structured medical interview. Informed consent was
obtained for the structured interviews. The medical ethical committee
approved the study.
Assessment instruments
Questionnaires were sent by post asking for age at the time of the study,
age at ﬁrst symptoms, age at diagnosis, type of SMA, inherited form of
SMA, frequency of and reason for hospitalization, frequency of surgery
and indication for surgery, co-morbidity (according to Ko¨nig-Zahn et al.
(14)), complaints/physical problems (list of 51 items based on literature
and an open answer question), frequency and type of medication, SIP-68
(15) for functional limitations and social demographic items. The
co-morbidity list (according to Ko¨nig-Zahn) is a general list for public
health studies, while the complaints/physical problems list was designed
specially for this study. An overlap of symptoms/physical complaints is
present. SIP-68 has been validated for the Dutch population including
neuromuscular disorders (15). If a person was unable to complete the
questionnaires they were advised to request support from a proxy.
A structured medical interview was performed by a trained physician
(IdG), since it is known that patients might give false negative answers in
chronic progressive disease, because they become gradually adjusted
and do not experience a physical impairment as a problem. The medical
interview was based on the section of functions and structure of the
ICIDH-2, now called ICF (WHO 2001 (16)).
Study population
Of the 190 questionnaires posted, 99 were returned (response rate 52%).
Based on the registration of the patients’ association (VSN) the
non-responders could be compared with the responders (Table I). The
non-responders had a shorter duration of the disease than did
the responders. In the non-responders slightly less SMA 1 and 2 were
reported. Twenty-three persons were selected for structured interviews
(cut-off points: see analysis); 4 did not give prior informed consent to an
interview, and thus 19 were invited. Of the selected persons 8 were men
and 11 women, mean age was 49 years (range 31–67 years), self-
reported type of SMA: 1 SMA-1, 3 SMA-2, 14 SMA-3 and 1 SMA-type
unknown. Ten persons agreed to a structured medical interview
(response rate 53%), 9 eventually participated (1 withdrew due to travel
distance): 3 men, 6 women, mean age 51.4 years (range 41–57);
2 reported to have SMA-2 and 7 SMA-3. The distribution of the SMA
types in the interviews is comparable to that of the responders group. In
the structured medical interviews age at ﬁrst symptoms and SMA type
were checked. Eight of the 9 persons could be classiﬁed as SMA type 3
and 1 as SMA type 2, although the latter had reported having type 3 and 2
of the SMA type 3 persons had said they had type 2.
Analysis
The reported type of SMA-1 is unlikely to be type 1 according to the
criteria of Emery (1); it would most probably be SMA-2. For this reason
we combined the results of SMA-1 and SMA-2 and named this group
SMA 1–2. A some of the responders did not know their type, but based
on their answers on age of ﬁrst symptoms, age at diagnosis and func-
tional abilities this group was most likely to be type 3. For this reason
their results were combined with SMA-3 and this group named SMA
3þ . Since the purpose of this study was to determine whether new
symptoms arise with increasing age, we divided the groups into persons
with a relatively short duration of the disease, a group with relatively
long duration of the disease and a mid-group (by means of dividing the
range of disease duration in three equal parts). For SMA 1–2 the chosen
cut-off points were disease duration shorter than 23 years and longer than
31 years, for SMA 3þ these cut-off points were shorter than 31 years
and longer than 42 years. These cut-off points were combined with cut-
off points for high functional limitations (SIP-scores) in order to select
the group with a severe disease course, since one would expect this group
to have the highest frequency of physical complaints related to the
disease duration.
SPSS-7.5 was used for statistical analysis. Descriptive analysis and
chi-square tests were performed.
RESULTS
Co-morbidity
Co-morbidity as reported on the general list of physical
problems (according to Ko¨nig-Zahn et al. (14)) lung problems
and high blood pressure were the most prevalent co-morbidities
(Table II). The prevalence of chronic speciﬁc lung disease is
much higher than in the normal population (18% vs 6%). In the
SMA 1–2 group the prevalence is higher than in the type 3þ
group: 34% vs 12%. In group SMA 1–2 the mean rate of
co-morbidity is higher than in group type 3þ : 0.8 vs 0.7. The
rate of co-morbidity tends to increase with ageing: if one divides
the duration of the disease into 3, the persons with the shortest
duration have mean co-morbidity rates of 0.4, compared with
0.9 for persons with the longest duration.
Physical complaints
Muscle weakness and cold hands and feet were most frequently
reported for both groups (Table III). Group SMA 1–2 shows a
signiﬁcantly higher prevalence for kyphoscoliosis, difﬁculty in
coughing, joint contractures and voice/speech problems
Table I. Study population
Responders
(n=99)
Non-responders
(n=91)
Men/Women (%) 45/55 57/40*
SMA-1 (%) 7 8
SMA-2 (%) 22 8
SMA-3 (%) 55 28
SMA-unknown (%) 15 43*
Mean disease duration (years) 34.4 22.2**
* Four persons missing item.
** 23 persons missing item; if the date of membership of the
patients’ association was taken as a date for diagnosis the mean
disease duration was 23.8 years.
SMA=spinal muscular atrophy.
Table II. Co-morbidity reported by the 99 persons who responded
Co-morbidity n (%)
Asthmatic/bronchitis 18 (18.2)
Cardiac diseases 2 (2.0)
High blood pressure 11 (11.1)
Stroke 0 (0)
Gastrointestinal 0 (0)
Liver 1 (1.0)
Renal 0 (0)
Diabetes mellitus 7 (7.1)
Back problems 7 (7.1)
Arthrosis 5 (5.1)
Rheumatoid diseases 0 (0)
Epilepsy 0 (0)
Cancer 2 (2.0)
Tuberculosis 0 (0)
Traumatic co-morbidity 5 (5.1)
Other 10 (10.1)
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compared with group SMA 3þ , while in the latter group fatigue
is signiﬁcantly more prevalent.
All physical complaints that were asked about are shown in
Table IV in order of duration of the complaint (from shortest to
longest based on SMA 1–2). There is a difference in pattern
between SMA 1–2 and SMA 3þ . No signiﬁcant correlation
could be found between symptoms and disease duration. In the
Dutch population the prevalence of physical complaints are all
below 9%, except for headache (mean 14%; Statistical Year-
book 2003). In this study problems with a prevalence of more
than 10% (headaches were omitted) and a mean appearance of
less than 10 years previously in group SMA 1–2 and a mean
appearance of less than 15 years previously for group SMA 3þ
were: concentration, sleepy during day, neck pain, intestinal
complaints, swallowing, joint pain and speech/voice (Table V).
The range of duration of these problems is wide, except for
concentration problems of both groups and sleepiness during the
day and neck pain for group SMA 1–2.
From the structured medical interviews only new or more
speciﬁed complaints with a high prevalence are reported here.
All 9 persons had sleep problems, especially sleeping without a
break: they woke up early in the night with (profuse) sweating.
Their partners also mentioned snoring and irregular breathing
during their sleep. All 9 persons had complaints of the throat
while swallowing: they had the idea that food was sticking there,
and 8 complained of retarded passage of the food in their
stomach and intestines. Seven persons mentioned palpitations.
Six had hypermobility in the joints of their upper extremities,
especially in their hands. Five persons mentioned suffusion of
the eyes and 1 had burning eyes. Five persons mentioned itching
of their buttocks and legs and sometimes their head.
DISCUSSION
The results of this study point to the appearance of physical
complaints related to increasing duration of the disease com-
bined with a more severe disease course. There are differences
and similarities in the patterns of physical complaints between
SMA 1–2 and 3þ .
The response rate for the questionnaires was 52%. The non-
responders reported more SMA type unknown, and had a shorter
duration of the disease. The SMA type unknown can be regarded
as SMA type 3 (see methods/analysis), and the disease course of
SMA 3 is generally less progressive (2, 3). The possibility of a
selection bias is likely, however, the bias may work positively
for the study by increasing the chance of the detection of new
physical complaints (since the aim was to explore persons with
SMA with the longest disease duration and a severe disease
course). The number of the participants in the structured inter-
views is very small, but all selected persons can be regarded as
being at risk for developing late (new) complaints. Their
distribution of SMA type was comparable to the primary
responders group.
SMA is divided into 3 types according to the onset of the ﬁrst
symptoms (1). However, nowadays SMA is regarded as a
disease with a gradual severity related to the onset of the
symptoms: onset at a young age predicts a more severe course
(2, 3). Although classiﬁed in 3 types there are no strong cut-off
points and the manifestation of the disease is regarded as a
range. Thus it can be expected that the appearance of physical
complaints is also gradual with a wide range of time of
appearance.
When we compare SMA 1–2 with SMA 3þ , a similar pattern
of complaints can be found, but there are also differences. The
group with SMA 1–2 can be regarded as the group with a more
severe disease course. This is reﬂected in the higher prevalence
of lung complaints in the co-morbidity questionnaire for
SMA 1–2. Respiratory muscle involvement is known in SMA,
and thus it is not a co-morbidity. However, the used
co-morbidity list makes it possible to compare SMA with the
general Dutch population. Signiﬁcantly different for SMA 1–2
are the higher percentages of kyphoscoliosis, joint contractures,
difﬁculty in coughing and speech and voice problems. This can
be explained by the fact that in SMA 1–2 the back muscles are
already (very) weak in youth. During growth a kyphoscoliosis
can develop that inﬂuences the functioning of the lungs. The
restricted lung function combined with the weakness of thorax
muscles thus can give rise to more difﬁculty in coughing. In the
most severe course of SMA, namely type 1, bulbar problems
such as swallowing problems are well known (17) and they are
also described in SMA type 2 at a lower frequency (9, 18). The
high percentage speech and voice problems in SMA 1–2 may be
related to bulbar involvement or to the restriction in lung
function. The cause cannot be deduced from the questionnaires.
A wide range of duration of the complaint is reported for all
physical complaints, including the more recent complaints. The
fact that persons are asked to recall the time of appearance
introduces possible bias. Another possible bias is that the
grouping was done based on the person’s own reported SMA
type. The interviews showed that this is not a very reliable way
for correct typing. Furthermore no DNA conﬁrmation of the
diagnosis was requested, again a possible source of bias.
Table III. Top 10 complaints among the persons in the groups
SMA 1–2 and SMA 3þ
Complaints
Group SMA 1–2 Group SMA 3þ
% Rank % Rank
Muscle weakness 97 1 89 1
Cold hands/feet 93 2 83 2
Kyphoscoliosis 90 3 36*** 9
Difﬁcult coughing 76 4 41** 7
Joint contractures 62 5 37* 8
Muscle trembling 55 6 47 6
Cold knees/calves 48 7 49 5
Swollen feet/legs 45 8 57 4
Choking 45 9 31%
Voice/ speech
problems
45 10 17*
Fatigue 34 61* 3
Neck pain 38 34 10
Statistical signiﬁcance between group SMA 1–2 and SMA 3þ:
* p<0.05; ** p<0.05; *** p<0.001.
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No signiﬁcant correlation could be found between the dura-
tion of the complaints and disease duration, probably due to the
wide range of time for all the physical complaints. We matched
the physical complaints with the shortest mean time of appear-
ance as indicated in the questionnaire with the interviews. The
swallowing and sleeping complaints stand out, indicating that
the concentration complaints and sleepiness during the day
revealed in the questionnaires may be highly related to the sleep
complaints reported in the interviews. It is striking that all 9
persons with the longest disease duration and most severe
disease course had swallowing and sleeping complaints. In the
interviews all phases of sleep and swallowing were investigated,
which is different from the questionnaire in which the questions
were more general. This can give rise to different prevalence
numbers. Sleep investigations involving SMA revealed periods
of hypoxaemia (19–21). Whether this is the cause of the waking
up sweating and the concentration problems and feeling sleepy
during the day is likely, but needs to be established.
Table IV. Physical complaints group SMA 1–2 and group SMA 3þ
Physical complaints
Group SMA 1–2 Group SMA 3þ
Mean years
(range)
No. (%)
(n=29) >10%=*
Mean years
(range)
No. (%)
(n=29) >10%=*
Hearing 3.5 (1–6) 2 (7) 37.5 (15–60) 2 (2.9)
Sleepy during day 4.4 (1–10) 7 (24) * 8.2 (1–25) 13 (18.6) *
High blood pressure 5.3 (3–10) 3 (10) 6.5 (2–10) 3 (4.3)
Neck pain 5.8 (3–10) 11 (38) * 10.5 (2–25) 24 (34.3) *
Periods 6.0 (6) 2 (7) 18.2 (3–29) 7 (10.0)
Excessive perspiration 7.3 (2–15) 7 (24) * 23.6 (2–55) 14 (20.0) *
Palpitations 7.3 (1–18) 3 (10) 17.3 (1–36) 13 (18.9) *
Joint pain 7.5 (1–22) 9 (31) * 11.8 (2–30) 17 (24.3) *
Concentration 7.8 (5–10) 4 (14) * 2.7 (1–5) 10 (14.3) *
Speech/voice 8.5 (1–23) 13 (45) * 12.2 (1–27) 12 (17.1) *
Skin pressure problems 8.6 (6–15) 5 (7) 15.2 (2–40) 14 (20.0) *
Opening mouth 9.1 (2–20) 12 (41) * 16.7 (10–43) 8 (11.4) *
Muscle pain 9.4 (2–25) 10 (34) * 19.1 (1–44) 22 (31.4) *
Swallowing 9.6 (2–20) 12 (41) * 11.8 (1–26) 17 (24.3) *
Sleep problems 9.7 (4–15) 3 (10) 14.8 (1–35) 12 (17.1) *
Intestinal 9.8 (4–15) 5 (17) * 11.7 (2–33) 12 (17.1) *
Headache 10.8 (4–21) 4 (14) * 9.7 (1–25) 17 (24.3) *
Muscle cramps 11.0 (2–20) 2 (7) 18.4 (1–44) 20 (28.6) *
Back pain 11.3 (5–20) 9 (31) * 12.9 (4–26) 19 (27.1) *
Dental 11.3 (2–16) 3 (10) 16.0 (5–25) 3 (4.3)
Overweight 12.0 (4–20) 3 (10) 15.9 (2–40) 16 (22.9) *
Defecation 12.5 (4–27) 11 (38) * 16.1 (1–37) 16 (22.9) *
Muscle trembling 13.3 (2–25) 16 (55) * 21.3 (2–50) 33 (47.1) *
Fatigue 13.4 (3–24) 10 (34) * 17.8 (1–54) 43 (61.4) *
Hyperventilation 13.5 (2–25) 2 (7) 8.7 (10–43) 9 (8.7)
Diaphragmatic 14.0 (10–18) 3 (10) 18.3 (10–30) 5 (7.1)
Eczema 14.1 (5–25) 8 (28) * 15.3 (1–40) 7 (10.0)
Muscle stiffness 14.6 (1–30) 9 (31) * 17.1 (1–44) 23 (32.9) *
Short of breath 14.9 (4–24) 10 (34) * 10.7 (1–20) 10 (14.3) *
Choking 15.0 (5–25) 13 (45) * 10.1 (1–27) 15 (21.4) *
Chewing 15.6 (2–21) 11 (38) * 12.8 (5–30) 16 (22.9) *
Tasting 16.0 (16) 1 (3)
Cold calf/knee 16.1 (2–27) 14 (48) * 25.1 (3–60) 34 (48.6) *
Bladder voiding 16.3 (9–25) 3 (10) 7.2 (1–20) 11 (15.7) *
Stomach 16.8 (8–40) 6 (21) * 16.4 (6–30) 9 (12.9) *
Underweight 17.2 (8–25) 5 (17) * 19.9 (1–30) 8 (11.4) *
Swollen feet/legs 17.3 (5–35) 13 (45) * 19.5 (4–47) 40 (57.1) *
Pulmonary infections 18.2 (6–24) 5 (17) * 15.0 (3–27) 5 (7.1)
Cold hands/feet 18.5 (2–35) 27 (93) * 23.1 (4–60) 58 (82.9) *
Kyphoscoliosis 19.4 (2–34) 26 (90) * 27.5 (3–51) 25 (35.7) *
Joint luxation 20.0 (15–23) 3 (10) 26.5 (1–50) 5 (7.1)
Difﬁcult coughing 20.4 (5–37) 22 (76) * 21.7 (5–50) 29 (41.4) *
Joint contractures 21.5 (10–45) 18 (62) * 27.6 (2–47) 26 (37.1) *
Seeing 21.0 (18–25) 3 (10) 12.3 (2–48) 13 (18.6) *
Muscle paralysis 22.2 (20–27) 8 (28) * 23.5 (1–50) 18 (25.7) *
Catarrh/bronchitis 22.0 (16–27) 5 (17) * 25.1 (1–40) 14 (20.0) *
Muscle weakness 23.6 (3–50) 28 (97) * 30.3 (4–55) 62 (88.6) *
Rest group
Potency Not mentioned 1 (3) 4.0 (3–5) 2 (2.9)
Low blood pressure 0 3.7 (5–8) 7 (10.0)
Menopause 0 8.5 (2–15) 4 (5.7)
Joint inﬂammation 0 3.0 (3) 2 (2.9)
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The interviews also revealed new problems: hypermobility in
the joints of the hand, problems with the suffusion of the eyes
and itching. Thus structured interviews elicited information
about complaints that were not noticed in the questionnaires.
Identiﬁcation of complaints is useful information for use in
developing interventions. For example, for the hypermobility in
the joints of the hands stabilizing orthoses can be tried out for a
functional gain in hand function. More insight into the patho-
physiological mechanisms of sleep problems and swallowing
problems can give clues for therapy.
Further research is needed to establish the extent of these
complaints for the whole population of persons with SMA and to
guide the therapeutic approaches.
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